Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc. (NDRA) is an imaging technology company developing the Thermo Acoustic Enhanced UltraSound (TAEUS®) platform, with a primary focus on liver fat quantification for steatotic liver disease (SLD) and metabolic dysfunction‑associated steatohepatitis (MASH). News about ENDRA frequently centers on clinical data, regulatory planning and strategic shifts that affect how its technology may be used in metabolic disease management and drug development.
Recent press releases highlight feasibility and pilot study results in which ENDRA’s thermo‑acoustic fat fraction (TAFF) measurements are compared with MRI‑PDFF, the recognized imaging gold standard for liver fat. These updates provide details on statistical agreement across the SLD spectrum, performance at clinically important liver fat thresholds, and the implications for patient stratification and monitoring in MASLD/MASH and GLP‑1 trials. Investors and clinicians can follow how enhancements to TAEUS Liver’s probe design and algorithms are expected to improve accuracy and repeatability ahead of a planned De Novo pivotal study.
ENDRA news also covers its evolving go‑to‑market strategy, including a pivot toward metabolic disease and GLP‑1 therapy management, identification of key customer segments such as pharmaceutical companies, CROs and metabolic clinics, and plans for a subscription‑based access model. In parallel, the company issues updates on its digital asset treasury (DAT) strategy, including private placements, HYPE token purchases, and staking initiatives managed by Arca Investment Management with custody by Anchorage Digital Bank.
By following NDRA news on this page, readers can track clinical milestones, regulatory interactions, capital markets activity, and developments in ENDRA’s DAT program, all of which shape the company’s trajectory in both medical imaging and digital asset management.
ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 and full-year 2025 results and a business update on March 31, 2026. The Board initiated an evaluation of strategic alternatives on March 25, 2026. Clinical milestones include TAEUS Liver feasibility results (Pearson r=0.89) and repeatability (ICC 0.89, SEM 3.3%).
Financials: 2025 operating expenses were $5.8M (down from $10.8M in 2024), net loss $7.0M (2024: $11.5M), cash and equivalents $762,000, and $2.0M held in a Digital Asset Treasury.
ENDRA Life Sciences (Nasdaq: NDRA) said its Board of Directors has launched a formal review of strategic alternatives to maximize shareholder value, including possible investments, mergers, collaborations, asset sales, or a sale of the company.
The Board engaged Lucid Capital Management as financial advisor and K&L Gates as legal counsel and said operations will continue while no timetable has been set for completion.
ENDRA (NASDAQ: NDRA) reported that its TAEUS Liver device achieved an intraclass correlation coefficient (ICC) of 0.89 and a standard error of measurement (SEM) of 3.3% in a clinical consistency study involving 14 subjects and 56 measurements.
Results indicate good-to-excellent intra-user repeatability and inter-user reproducibility, suggesting the device can deliver MRI-level quantitative liver fat consistency at the point of care and lower cost for monitoring MASLD.
ENDRA (NASDAQ: NDRA) reported 2025 feasibility results showing its TAEUS thermo-acoustic fat fraction (TAFF) measurement closely tracks MRI-PDFF at clinical liver fat fraction thresholds used for MASLD/MASH trials.
Key data from 40 subjects: 12–17% LFF average PPV 100%, NPV 94%, Accuracy 95%; 20–22% LFF average PPV 90%, NPV 94%, Accuracy 94%. TAEUS aims to offer point-of-care scans at under $200 vs MRI exams often >$2,500, supporting frequent monitoring and potential trial cost reductions. A second feasibility study is underway and ENDRA plans FDA engagement in 2026 on a pivotal study design.
ENDRA Life Sciences (NASDAQ: NDRA) reported preliminary results from a single-site feasibility study showing its 2025 optimized TAEUS Liver device quantifies liver fat fraction closely aligned with MRI‑PDFF, the imaging gold standard.
Key metrics: 40 subjects (BMI 21–47), Deming regression slope=1 and intercept=0 within 95% CIs, Pearson r=0.89, >90% of subjects within a 5% error margin and average error ~3%. ENDRA plans FDA pre‑submission meetings and a pivotal study; a second feasibility study is underway in Canada.
ENDRA Life Sciences (Nasdaq: NDRA) reported business and Q3 2025 results on November 17, 2025, highlighting financing, balance-sheet actions and clinical progress for its TAEUS® liver imaging device.
Key facts: the company closed a PIPE that generated gross proceeds of approximately $4.9 million on October 23, 2025, with potential additional proceeds of $9.5 million via warrant exercises; regained Nasdaq compliance with Rule 5550(b)(1); reduced cash burn from operations by 30% to $1.2 million in Q3 2025; Q3 operating expenses were $1.4 million versus $1.5 million a year ago; cash and equivalents were $0.8 million at September 30, 2025; and the company completed a single-site clinical feasibility study of the redesigned TAEUS® device with results to be released soon.
ENDRA Life Sciences (Nasdaq: NDRA) has commenced staking its holdings of HYPE, the native token of the Hyperliquid ecosystem, as part of a digital asset treasury strategy announced on November 13, 2025. Guided by ARCA Investment Management and using institutional custody and staking services from Anchorage Digital, ENDRA deployed its HYPE position into a secure staking solution following its initial HYPE investment on October 23, 2025.
The company says staking will generate network rewards, support Hyperliquid network security and decentralization, and provide strategic access to potential governance and DeFi opportunities while aligning with its disciplined treasury management approach.
ENDRA Life Sciences (Nasdaq: NDRA) closed a private placement financing that generated gross proceeds of approximately $4.9 million with potential for up to an additional $9.5 million from warrant exercises. Concurrently, the company launched a digital asset treasury strategy and acquired 78,863.1 HYPE tokens, valued at approximately $3.0 million as of October 21, 2025.
The DAT strategy targets long-term token exposure plus active yield techniques (options overlays, staking, DeFi participation) with trade‑ and portfolio‑level risk controls, aiming to grow tokens‑per‑share, generate reinvestable income, and create optionality for crypto‑related M&A and capital activities. Lucid Capital Markets acted as sole placement agent.
ENDRA Life Sciences (Nasdaq: NDRA) announced $4.9 million in committed proceeds from an at-market private placement to fund a new digital asset treasury (DAT) strategy managed with Arca, and intends to appoint Arca CIO Jeff Dorman to its Digital Asset Advisory Board.
The purchase agreement covers 744,340 shares (or pre-funded warrants) and accompanying warrants to buy up to 1,488,680 shares, sold at a combined price of $6.57. Warrants are exercisable immediately at $6.32 and expire in five years; pre-funded warrants carry a $0.0001 exercise price. If all warrants are exercised, gross proceeds could reach $14.4 million. Majority of net proceeds will go to DAT operations and crypto accumulation; remaining proceeds to complete the TAEUS pilot validation imaging study for MASLD/MASH.
ENDRA Life Sciences (NASDAQ: NDRA), developer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), reported Q2 2025 financial results and provided key business updates. The company has made significant progress in its TAEUS Liver system development, with initial testing showing major accuracy improvements against MRI-PDFF measurements.
ENDRA plans to conduct a 250-subject multisite clinical trial for FDA De Novo submission by year-end. The company has expanded its patent portfolio to 85 issued patents globally and implemented substantial cost reductions, resulting in a 42% decrease in Q2 operating expenses to $1.2 million. Cash position stands at $1.8 million as of June 30, 2025, with quarterly cash burn reduced to $1.1 million.